SOMAVERT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SOMAVERT (SOMAVERT).
Pegvisomant is a growth hormone receptor antagonist. It binds to GH receptors on cell surfaces, blocking endogenous GH binding and thereby inhibiting IGF-1 production, which is the primary mediator of GH effects.
| Metabolism | Metabolized primarily in the liver via unknown pathways; not significantly metabolized by cytochrome P450 enzymes. |
| Excretion | Renal: >95% as unchanged drug via glomerular filtration; fecal: <5% |
| Half-life | Terminal elimination half-life: 6-7 days (pegvisomant); clinical context: allows weekly subcutaneous dosing |
| Protein binding | >90% bound to serum albumin and to growth hormone binding protein (GHBP) |
| Volume of Distribution | Vd: 0.4-0.6 L/kg; clinical meaning: indicates distribution primarily into extracellular fluid, consistent with low tissue penetration due to pegylation |
| Bioavailability | Subcutaneous: 53% (absolute bioavailability) |
| Onset of Action | Subcutaneous: reduction in serum IGF-1 levels observed within 1-2 weeks of initiating therapy |
| Duration of Action | Subcutaneous: sustained suppression of IGF-1 for up to 7 days; clinical notes: monitoring of IGF-1 levels is recommended every 4-8 weeks to titrate dose |
Subcutaneous injection: Loading dose 40 mg, then 10 mg daily. May be increased to 15 mg daily if IGF-I levels not normalized after 4 weeks. Maximum dose 40 mg daily.
| Dosage form | INJECTABLE |
| Renal impairment | For GFR 20-80 mL/min: No adjustment. For GFR <20 mL/min: Reduce dose by 50% (e.g., 20 mg loading, then 5 mg daily); monitor IGF-I response and titrate carefully. |
| Liver impairment | No specific Child-Pugh based guidelines. Caution in severe hepatic impairment; use lower starting doses and titrate based on clinical response and IGF-I levels. |
| Pediatric use | Not approved for pediatric use (safety and efficacy not established). |
| Geriatric use | No specific dose adjustment; start at lower end of dosing range (10 mg daily after loading) and monitor renal function and IGF-I levels. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SOMAVERT (SOMAVERT).
| Breastfeeding | No human data on excretion in breast milk. M/P ratio unknown. Because pegvisomant is a large protein (MW ~40 kDa), transfer into breast milk is likely minimal. Caution advised; consider discontinuing nursing or drug based on importance to mother. |
| Teratogenic Risk | Teratogenic risk in pregnancy is not fully characterized. In animal studies, pegvisomant crosses the placenta and caused fetal growth restriction at maternal toxic doses. Human data are limited. First trimester: theoretical risk due to IGF-1 suppression; second and third trimesters: risk of fetal growth restriction and potential fetal pituitary suppression. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to pegvisomant or any of its components."]
| Precautions | ["Hepatotoxicity (elevated liver enzymes, hepatitis, hepatic failure; monitor LFTs), lipodystrophy at injection site, allergic reactions, growth hormone deficiency exacerbation, tumor growth potential, insulin sensitivity changes (may improve glycemic control)."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal IGF-1 levels (target normalization), liver enzymes, and blood glucose. If continued in pregnancy, monitor fetal growth by ultrasound and consider monitoring for fetal pituitary-adrenal axis suppression. |
| Fertility Effects | In female rats, pegvisomant increased estrous cycle length and reduced fertility at high doses. In humans, no fertility studies; however, acromegaly itself may impair fertility, and treatment with pegvisomant may restore fertility by normalizing GH/IGF-1. |